TerminatedPhase 3

Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment

United States281 participantsStarted 2012-10

Plain-language summary

The purpose of this study is to evaluate the efficacy of gevokizumab in reducing the risk of recurrent uveitic disease in subjects with non-infectious uveitis whose disease is currently controlled with systemic treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of non-infectious intermediate, posterior, or pan- uveitis in at least one eye * Controlled uveitic disease in both eyes * Stable dose of oral corticosteroids in combination with selected stable immunosuppressive therapy * Effective contraceptive measures Exclusion Criteria: * Infectious uveitis and masquerade syndromes * Isolated anterior uveitis * Contraindication to mydriatics * Active tuberculosis disease * History of allergic or anaphylactic reactions to monoclonal antibodies * History of recurrent infection or predisposition to infection; active ocular infection * Pregnant or nursing women Other protocol-defined inclusion/exclusion criteria may apply

What they're measuring

Proportion of subjects with an occurrence of uveitic disease through Day 168

Timeframe: Day 0 through Day 168

Trial details

NCT IDNCT01747538

SponsorXOMA (US) LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2016-06

View on ClinicalTrials.gov More Uveitis trials